Mylan, Somaxon settle insomnia drug suit

Mylan can sell generic version starting Jan. 1, 2020, or earlier

PITTSBURGH — Mylan has settled a patent litigation suit filed by Somaxon Pharmaceutical concerning an insomnia drug, Mylan said.

The generic drug maker said that under the settlement, it would have the right to sell doxepin hydrochloride tablets in the 3-mg and 6-mg strengths starting in January 2020. The drug is a generic version of Somaxon's Silenor.

Mylan will have the right to sell its generic version of Silenor for 180 days under a license from Somaxon, a period that may be extended for up to 360 days, after which Mylan can sell its version of the drug under its own regulatory approval application.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.